Profiling the expression of cytochrome P450 in breast cancer

Graeme I Murray, Siva Patimalla, Keith N Stewart, Iain D Miller, Steve D Heys

Research output: Contribution to journalArticle

70 Citations (Scopus)

Abstract

Aims
The cytochrome P450s are key oxidative enzymes which metabolise of carcinogens and anti-cancer drugs. Thus these enzymes influence tumour development, tumour response to therapy and are putative tumour biomarkers. The purpose of this study was to define the cytochrome P450 expression profile in breast cancer and establish the significance of cytochrome P450 expression in this tumour type.
Methods and results
A tissue microarray containing 170 breast cancers of no special type was immunostained for a panel of 21 cytochrome P450s. The highest percentage of strongly positive staining in breast cancers was seen for CYP4X1 (50.8%), CYP2S1 (37.5%) and CYP2U1 (32.2%) respectively, while CYP2J (98.6%) and CYP3A43 (70.7%) were the cytochrome P450s that most frequently displayed no immunoreactivity respectively. CYP4V2 (p=0.01), CYP4X1 (p=0.01) and CYP4Z1 (p=0.01) showed correlations with tumour grade. CYP1B1 (p=0.001), CYP3A5 (p=0.001) and CYP51 (p=0.005) were the cytochrome P450s which showed the most significant correlations with oestrogen receptor status. Correlations with survival were identified for CYP2S1 (p=0.03), CYP3A4 (p=0.025), CYP4V2 (p=0.026) and CYP26A1 (p=0.03).
Conclusions
This study has defined the expression profile of cytochrome P450 in breast cancer and and may offer the potential application as biomarkers to aid decisions regarding optimal adjuvant therapy.
Original languageEnglish
Pages (from-to)202-211
Number of pages10
JournalHistopathology
Volume57
Issue number2
DOIs
Publication statusPublished - Aug 2010

Fingerprint

Cytochrome P-450 Enzyme System
Cytochromes
Breast Neoplasms
Cytochrome P-450 CYP3A
Neoplasms
Decision Support Techniques
Enzymes
Tumor Biomarkers
Estrogen Receptors
Carcinogens
Biomarkers
Staining and Labeling
Therapeutics
Pharmaceutical Preparations
cytochrome P-450 4X1

Keywords

  • breast cancer
  • cytochrome P450
  • immunohistochemistry
  • prognosis
  • survival
  • tissue microarray

Cite this

Murray, G. I., Patimalla, S., Stewart, K. N., Miller, I. D., & Heys, S. D. (2010). Profiling the expression of cytochrome P450 in breast cancer. Histopathology, 57(2), 202-211. https://doi.org/10.1111/j.1365-2559.2010.03606.x

Profiling the expression of cytochrome P450 in breast cancer. / Murray, Graeme I; Patimalla, Siva; Stewart, Keith N; Miller, Iain D; Heys, Steve D.

In: Histopathology, Vol. 57, No. 2, 08.2010, p. 202-211.

Research output: Contribution to journalArticle

Murray, GI, Patimalla, S, Stewart, KN, Miller, ID & Heys, SD 2010, 'Profiling the expression of cytochrome P450 in breast cancer', Histopathology, vol. 57, no. 2, pp. 202-211. https://doi.org/10.1111/j.1365-2559.2010.03606.x
Murray, Graeme I ; Patimalla, Siva ; Stewart, Keith N ; Miller, Iain D ; Heys, Steve D. / Profiling the expression of cytochrome P450 in breast cancer. In: Histopathology. 2010 ; Vol. 57, No. 2. pp. 202-211.
@article{3d226cbd4f664af28fd016eaa8f8c4b9,
title = "Profiling the expression of cytochrome P450 in breast cancer",
abstract = "Aims The cytochrome P450s are key oxidative enzymes which metabolise of carcinogens and anti-cancer drugs. Thus these enzymes influence tumour development, tumour response to therapy and are putative tumour biomarkers. The purpose of this study was to define the cytochrome P450 expression profile in breast cancer and establish the significance of cytochrome P450 expression in this tumour type. Methods and results A tissue microarray containing 170 breast cancers of no special type was immunostained for a panel of 21 cytochrome P450s. The highest percentage of strongly positive staining in breast cancers was seen for CYP4X1 (50.8{\%}), CYP2S1 (37.5{\%}) and CYP2U1 (32.2{\%}) respectively, while CYP2J (98.6{\%}) and CYP3A43 (70.7{\%}) were the cytochrome P450s that most frequently displayed no immunoreactivity respectively. CYP4V2 (p=0.01), CYP4X1 (p=0.01) and CYP4Z1 (p=0.01) showed correlations with tumour grade. CYP1B1 (p=0.001), CYP3A5 (p=0.001) and CYP51 (p=0.005) were the cytochrome P450s which showed the most significant correlations with oestrogen receptor status. Correlations with survival were identified for CYP2S1 (p=0.03), CYP3A4 (p=0.025), CYP4V2 (p=0.026) and CYP26A1 (p=0.03). Conclusions This study has defined the expression profile of cytochrome P450 in breast cancer and and may offer the potential application as biomarkers to aid decisions regarding optimal adjuvant therapy.",
keywords = "breast cancer, cytochrome P450, immunohistochemistry, prognosis, survival, tissue microarray",
author = "Murray, {Graeme I} and Siva Patimalla and Stewart, {Keith N} and Miller, {Iain D} and Heys, {Steve D}",
year = "2010",
month = "8",
doi = "10.1111/j.1365-2559.2010.03606.x",
language = "English",
volume = "57",
pages = "202--211",
journal = "Histopathology",
issn = "0309-0167",
publisher = "Blackwell Publishing",
number = "2",

}

TY - JOUR

T1 - Profiling the expression of cytochrome P450 in breast cancer

AU - Murray, Graeme I

AU - Patimalla, Siva

AU - Stewart, Keith N

AU - Miller, Iain D

AU - Heys, Steve D

PY - 2010/8

Y1 - 2010/8

N2 - Aims The cytochrome P450s are key oxidative enzymes which metabolise of carcinogens and anti-cancer drugs. Thus these enzymes influence tumour development, tumour response to therapy and are putative tumour biomarkers. The purpose of this study was to define the cytochrome P450 expression profile in breast cancer and establish the significance of cytochrome P450 expression in this tumour type. Methods and results A tissue microarray containing 170 breast cancers of no special type was immunostained for a panel of 21 cytochrome P450s. The highest percentage of strongly positive staining in breast cancers was seen for CYP4X1 (50.8%), CYP2S1 (37.5%) and CYP2U1 (32.2%) respectively, while CYP2J (98.6%) and CYP3A43 (70.7%) were the cytochrome P450s that most frequently displayed no immunoreactivity respectively. CYP4V2 (p=0.01), CYP4X1 (p=0.01) and CYP4Z1 (p=0.01) showed correlations with tumour grade. CYP1B1 (p=0.001), CYP3A5 (p=0.001) and CYP51 (p=0.005) were the cytochrome P450s which showed the most significant correlations with oestrogen receptor status. Correlations with survival were identified for CYP2S1 (p=0.03), CYP3A4 (p=0.025), CYP4V2 (p=0.026) and CYP26A1 (p=0.03). Conclusions This study has defined the expression profile of cytochrome P450 in breast cancer and and may offer the potential application as biomarkers to aid decisions regarding optimal adjuvant therapy.

AB - Aims The cytochrome P450s are key oxidative enzymes which metabolise of carcinogens and anti-cancer drugs. Thus these enzymes influence tumour development, tumour response to therapy and are putative tumour biomarkers. The purpose of this study was to define the cytochrome P450 expression profile in breast cancer and establish the significance of cytochrome P450 expression in this tumour type. Methods and results A tissue microarray containing 170 breast cancers of no special type was immunostained for a panel of 21 cytochrome P450s. The highest percentage of strongly positive staining in breast cancers was seen for CYP4X1 (50.8%), CYP2S1 (37.5%) and CYP2U1 (32.2%) respectively, while CYP2J (98.6%) and CYP3A43 (70.7%) were the cytochrome P450s that most frequently displayed no immunoreactivity respectively. CYP4V2 (p=0.01), CYP4X1 (p=0.01) and CYP4Z1 (p=0.01) showed correlations with tumour grade. CYP1B1 (p=0.001), CYP3A5 (p=0.001) and CYP51 (p=0.005) were the cytochrome P450s which showed the most significant correlations with oestrogen receptor status. Correlations with survival were identified for CYP2S1 (p=0.03), CYP3A4 (p=0.025), CYP4V2 (p=0.026) and CYP26A1 (p=0.03). Conclusions This study has defined the expression profile of cytochrome P450 in breast cancer and and may offer the potential application as biomarkers to aid decisions regarding optimal adjuvant therapy.

KW - breast cancer

KW - cytochrome P450

KW - immunohistochemistry

KW - prognosis

KW - survival

KW - tissue microarray

U2 - 10.1111/j.1365-2559.2010.03606.x

DO - 10.1111/j.1365-2559.2010.03606.x

M3 - Article

VL - 57

SP - 202

EP - 211

JO - Histopathology

JF - Histopathology

SN - 0309-0167

IS - 2

ER -